Target type: biologicalprocess
Any process that stops, prevents or reduces the frequency, rate or extent of CD8-positive, alpha-beta T cell activation. [GOC:obol]
Negative regulation of CD8-positive, alpha-beta T cell activation is a crucial process in maintaining immune homeostasis and preventing autoimmunity. It involves a complex interplay of signaling pathways and regulatory mechanisms that suppress the activation of CD8+ T cells, which are essential for recognizing and eliminating virally infected cells and tumor cells.
CD8+ T cell activation is initiated by the recognition of antigen presented by major histocompatibility complex (MHC) class I molecules on antigen-presenting cells (APCs), such as dendritic cells. This interaction triggers a cascade of signaling events, leading to the production of cytokines, cell proliferation, and differentiation into effector T cells.
However, uncontrolled activation of CD8+ T cells can result in autoimmune diseases, where the immune system mistakenly attacks healthy cells. Therefore, negative regulation of CD8+ T cell activation is essential for maintaining tolerance to self-antigens and preventing these harmful responses.
Several mechanisms contribute to the negative regulation of CD8+ T cell activation:
1. **Inhibitory Receptors:** CD8+ T cells express inhibitory receptors, such as CTLA-4 and PD-1, which bind to ligands on APCs. These interactions deliver inhibitory signals that dampen T cell activation by interfering with downstream signaling pathways.
2. **Regulatory T Cells (Tregs):** Tregs are a specialized subset of T cells that suppress the activation of other T cells, including CD8+ T cells. They express the transcription factor Foxp3, which is essential for their suppressive function. Tregs can suppress CD8+ T cell activation through various mechanisms, including production of inhibitory cytokines like IL-10 and TGF-β, and by directly interacting with CD8+ T cells.
3. **Cytokine Signaling:** Certain cytokines, such as IL-10 and TGF-β, have an inhibitory effect on CD8+ T cell activation. These cytokines can suppress T cell proliferation, cytokine production, and effector function.
4. **Apoptosis:** In some cases, CD8+ T cells may undergo apoptosis, or programmed cell death, as a mechanism to prevent excessive activation and potential autoimmune damage.
5. **Metabolic Regulation:** The metabolic state of CD8+ T cells influences their activation and function. Negative regulators can influence metabolic pathways, limiting the availability of resources needed for full activation.
6. **Microenvironment:** The local environment within tissues can also influence the activation of CD8+ T cells. Factors like the presence of other immune cells, chemokines, and matrix proteins can contribute to the regulation of T cell activation.
Overall, the negative regulation of CD8+ T cell activation is a complex process involving multiple levels of control. These mechanisms ensure that the immune response is appropriately tailored to the specific threat, preventing excessive inflammation and maintaining immune tolerance. '
"
Protein | Definition | Taxonomy |
---|---|---|
Programmed cell death 1 ligand 1 | A programmed cell death 1 ligand 1 that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q9NZQ7] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
sesamin | (+)-sesamin : A lignan that consists of tetrahydro-1H,3H-furo[3,4-c]furan substituted by 1,3-benzodioxole groups at positions 1 and 4 (the 1S,3aR,4S,6aR stereoisomer). Isolated from Cinnamomum camphora, it exhibits cytotoxic activity. | benzodioxoles; furofuran; lignan | antineoplastic agent; neuroprotective agent; plant metabolite |
pomalidomide | 3-aminophthalimidoglutarimide: structure in first source | aromatic amine; dicarboximide; isoindoles; piperidones | angiogenesis inhibitor; antineoplastic agent; immunomodulator |
apiin | apiin : A beta-D-glucoside having a beta-D-apiosyl residue at the 2-position and a 5,4'-dihydroxyflavon-7-yl moiety at the anomeric position. apiin: structure | beta-D-glucoside; dihydroxyflavone; glycosyloxyflavone | EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; plant metabolite |
fosbretabulin | stilbenoid |